MR MRK Merck & Co., Inc. Loading... : Bullish and Bearish Analyst Opinions

In dermatology, management acknowledges pressure from competition and promotional activity on Apoquel, but notes that switching from Cytopoint and Apoquel chewable has been limited, indicating brand loyalty within the franchise and that the competitive threat is primarily on new patient starts. — The competitive share erosion in the dermatology market is concentrated on acquiring new patients; the inability to convert existing patients limits the potential upside for a new entrant like Merck's Zenrelia and points to a slower, more costly ramp-up.